Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer to enable liberalization of potassium restriction in chronic dialysis patients
2025-521378-33-00Phase 3Authorised
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jul 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing Patiromer with Placebo (2 arms). Primary endpoint: Low-potassium diet withdrawal and/or down-titration. Planned start Jul 2025; status: authorised.
02
Drugs
patiromer
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2025-521378-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521378-33-00.